The UCLA Center for the Study of Parkinson's Disease will use an integrated multidisciplinary approach to elucidate the effects of nigrostriatal lesions and treatments of Parkinson's disease on the molecular and cellular characteristics of the subthalamic nucleus. This region of the basal ganglia has recently emerged as an important focus for the development of novel therapeutic strategies for the disease. The goal of the Center will be to identify new molecular targets for non-invasive pharmacological treatments for Parkinson's disease. The techniques of molecular neuroanatomy, slice electrophysiology, in vivo microdialysis and behavioral analysis will be used in four animal models: I) rats with nigrostriatal lesions; 2) lesioned rats treated with L-DOPA; 3) lesioned rats with chronic deep brain stimulation of the subthalamic nucleus; 4) lesioned rats with implanted OABA producing cells in the subthalamic nucleus. Key findings will be examined with molecular anatomical techniques in post-mortem human brain. Research in the Center will be supported by an Administrative and Communication core. In addition, an Animals and Neuropathology (Core B), Molecular Biology (Core C), and Neuroengineering (Core D) cores will provide standardized research tools for all projects and develop new cutting edge technology to enhance research in the Center. Core B will provide standardized surgical, behavioral, histological and neurochemical procedures for all the animal models examined in the Center, and will collect well characterized brains form patients with Parkinson's disease for study of the subthalamic nucleus. Core C will provide all projects with GABA-producing cells for in vivo transplantation, and will identify changes in gene expression with DNA microarray technology. Core D will develop and manufacture deep brain stimulation probes for rats and develop miniaturized probes for measuring neurotransmitter release. Interactions between the Center and clinical investigators in the Movement Disorder Program at UCLA will provide an ideal conduit for the rapid translation of research findings into clinical applications. The Center will provide a dynamic training environment that will expand the research capabilities of scientists at all career levels and their trainees. The Center will facilitate the participation of new investigators across the UCLA campus in research on Parkinson's disease and will reinforce the existing interactions between basic and clinical research on Parkinson's disease at UCLA.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
3P50NS038367-05S2
Application #
7100671
Study Section
Special Emphasis Panel (ZNS1)
Program Officer
Murphy, Diane
Project Start
1999-09-30
Project End
2005-07-31
Budget Start
2003-08-01
Budget End
2005-07-31
Support Year
5
Fiscal Year
2005
Total Cost
$154,500
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kusters, Cynthia D J; Paul, Kimberly C; Guella, Ilaria et al. (2018) Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 47:39-44
Chen, Honglei; Ritz, Beate (2018) The Search for Environmental Causes of Parkinson's Disease: Moving Forward. J Parkinsons Dis 8:S9-S17
Richter, Franziska; Subramaniam, Sudhakar R; Magen, Iddo et al. (2017) A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing ?-Synuclein. Neurotherapeutics 14:1107-1119
Mata, Ignacio F; Johnson, Catherine O; Leverenz, James B et al. (2017) Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. Neurobiol Aging 56:211.e1-211.e7
Paul, Kimberly C; Sinsheimer, Janet S; Cockburn, Myles et al. (2017) Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environ Int 107:75-81
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102
Paul, Kimberly C; Rausch, Rebecca; Creek, Michelle M et al. (2016) APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression. J Parkinsons Dis 6:349-59
Paul, Kimberly C; Sinsheimer, Janet S; Rhodes, Shannon L et al. (2016) Organophosphate Pesticide Exposures, Nitric Oxide Synthase Gene Variants, and Gene-Pesticide Interactions in a Case-Control Study of Parkinson's Disease, California (USA). Environ Health Perspect 124:570-7
Kannarkat, G T; Cook, D A; Lee, J-K et al. (2015) Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control Study. NPJ Parkinsons Dis 1:
Lee, P C; Bordelon, Y; Bronstein, J et al. (2015) Head injury, ?-synuclein genetic variability and Parkinson's disease. Eur J Neurol 22:874-8

Showing the most recent 10 out of 115 publications